Stock FDMT 4D MOLECULAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
23.53 USD -2.97% Intraday chart for 4D Molecular Therapeutics, Inc. -5.04% +16.14%
Apr. 15 Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target MT
Apr. 15 RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target
MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier
MT
Certain Restricted Stock Units of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
Certain Stock Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing
MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating
MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating
MT
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis
MT
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
GL
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
CI
Transcript : 4D Molecular Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
4DMT to Participate in Upcoming Investor Conferences
GL
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
GL
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
GL
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
AQ
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024
CI
4d Molecular Therapeutics Insider Sold Shares Worth $737,788, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. News 4D Molecular Therapeutics, Inc.